As an example, SLC29A1 and DCK silencing via DNA methylation in some gemcitabine-resistant pancreatic cancer patients could be targeted with a pharmaco-epigenetic approach using DNMT inhibitors alongside gemcitabine [30]. This evidence concerns the gene DCK and pancreatic neoplasm.